Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans

Status Not yet recruiting

Clinical Trial Summary

The oligosaccharide content (raffinose, stachyose, and verbascose) in legumes would be responsible for gastrointestinal symptoms (bloating, pain, meteorism), associated with its consumption.

We would evaluate consumption of 3 varieties of chilean native beans, and evaluate gastrointestinal symptoms produced along with expired H2 test, to correlate this with the amount of oligosaccharide content.

Clinical Trial Description

Different varieties of legumes have different oligosaccharide contents, in a study in Poland, it is described that the content of stachyose between 3 varieties can be as different as 493 mg, 865 mg or 1200 mg per 100 grams of dried beans (Slupski 2014). Along with this it has been described that the different culinary preparations of the legumes decrease the anti-nutritional factors, so, when soaking for 6 hours it shows 16.5% of undigested sugars reaching the small intestine, but it is possible to digest 95% in the colon (Noah 1998). Soaking for 16 hours, decreases 85% phytate content, 84% tannin content, 25% raffinose content, 25% stachyose and 41% verbascose (Hurtado 2001).

The oligosaccharide content (raffinose, stachyose, and verbascose) would be responsible for gastrointestinal symptoms (bloating, pain, meteorism), associated with legume consumption.

This is because these sugars are galactooligosaccharides, which are not digested in the human intestine because it does not have an alpha-galactosidase enzyme (Hessels 2003).

In our study, 25 varieties of Chilean bean are being evaluated, with nutritional analysis, resulting in a variation between 18 and 25 grams of protein per 100 grams dry (unpublished data), the oligosaccharide content still pending will be evaluated for Select the 3 varieties that contain more proteins and less oligosaccharides.

These varieties with better nutritional "profile" will be selected, to be evaluated clinically. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04243187
Study type	Interventional
Source	University of Chile
Contact	Natalia M Jara, MD
Phone	+56993499361
Email	Nmjara@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	April 1, 2020
Completion date	October 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT03566160` - Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy	N/A
Active, not recruiting	`NCT05053191` - Advancing Nursing Practices in Hospital Oncology Care	N/A
Recruiting	`NCT03602677` - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage	N/A
Recruiting	`NCT04138225` - The Ecological Role of Yeasts in the Human Gut
Completed	`NCT00671177` - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique	N/A
Completed	`NCT00910104` - Cholestasis Reversal: Efficacy of IV Fish Oil	Phase 2/Phase 3
Recruiting	`NCT06236594` - Application of Multimodal Endoscopic Functional Imaging Technology in the Diagnosis of Common Gastrointestinal Diseases
Completed	`NCT05409196` - Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults	Phase 1
Enrolling by invitation	`NCT04719117` - Retrograde Cholangiopancreatography AI Assisted System Validation on Effectiveness and Safety
Recruiting	`NCT03719209` - Using Virtual Reality for Patients With Gastrointestinal Disease	N/A
Enrolling by invitation	`NCT03319446` - Collection of Anonymized Samples	N/A
Enrolling by invitation	`NCT03234543` - Remote Ischemic Conditioning in Abdominal Surgery	N/A
Completed	`NCT04498208` - Immune Modulation by Enhanced vs Standard Prehabilitation Program Before Major Surgery	N/A
Completed	`NCT03559543` - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Phase 2
Completed	`NCT03549494` - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction	Phase 2
Completed	`NCT03723447` - Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)	Phase 4
Not yet recruiting	`NCT04514042` - Comparison of Zenker's Diverticulum Treatment Using Peroral Endoscopic Myotomy and Flexible Endoscopy Septotomy.	N/A
Suspended	`NCT04519086` - The Optimization of a Low-dose CT Protocol in Patients With Suspected Uncomplicated Acute Appendicitis and BMI >30	N/A
Completed	`NCT03019042` - Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Non-organic Gastrointestinal Disorders	N/A
Completed	`NCT05008640` - Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms